AMT-130 Breakthrough: 75% Slower Huntington's | AcademicJobs UK
NIHR-backed AMT-130 trial at UCL and Cardiff shows 75% slower Huntington's progression, marking a historic advance in gene therapy research.
No reviews yet. Be the first to rate Sarah!
Professor Sarah Tabrizi is Joint Head of the Department of Neurodegenerative Diseases at the UCL Queen Square Institute of Neurology and Director of the UCL Huntington’s Disease Centre, which she co-founded in 2016. She is also a Principal Investigator at the UK Dementia Research Institute at UCL and an Honorary Consultant Neurologist at the National Hospital for Neurology and Neurosurgery, where she established the Multidisciplinary Huntington’s Disease Clinic. Tabrizi graduated with a first-class degree in biochemistry from Heriot-Watt University in 1986 and an MBChB from the University of Edinburgh in 1992, where she was awarded the Gold Medal as the most distinguished medical graduate. She obtained a PhD from University College London in 2000 on mitochondrial dysfunction in neurodegeneration.
Tabrizi was promoted to Clinical Senior Lecturer and Honorary Consultant Neurologist in 2003, Reader in 2007, and Professor of Clinical Neurology in 2009. Her research focuses on mechanisms of cellular neurodegeneration, with particular emphasis on Huntington’s disease pathobiology, biomarkers, outcome measures, and therapeutic development, including leading international studies such as TRACK-HD and the Huntington’s Disease Young Adult Study. She has authored more than 425 publications with over 48,000 citations and an h-index of 115. Tabrizi has received numerous honours, including election as a Fellow of the Royal Society in 2024, the US National Academy of Medicine in 2024, the MRC Millennium Medal in 2022, and the CBE in 2026. She has served as global lead clinical investigator on the first huntingtin-lowering antisense oligonucleotide trial in Huntington’s disease and contributed to the development of the Huntington’s Disease Integrated Staging System.
NIHR-backed AMT-130 trial at UCL and Cardiff shows 75% slower Huntington's progression, marking a historic advance in gene therapy research.
Photo by Mufid Majnun on Unsplash
Photo by Shubham Sharan on Unsplash
Photo by Shubham Sharan on Unsplash
Photo by Evan Marvell on Unsplash
Photo by Markus Winkler on Unsplash
Photo by Patrick Robert Doyle on Unsplash
Photo by Brandi Redd on Unsplash
Have a story or a research paper to share? Become an Expert Academic Contributor and publish your work on AcademicJobs.com.
Write news and research articles as a expert academic in your field publish your work on AcademicJobs.com
